Table 5 Expression of ER, PR, HER 2 and EGFR by biomarkers whose expression significantly differed between subtypes
| Â | ER | P | PR | P | HER2 | P | EGFR | P | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biomarkers | Positive (%) | Negative (%) | Positive (%) | Negative (%) | Positive (%) | Negative (%) | Positive (%) | Negative (%) | ||||
PTEN | 0.76 | Â | Â | 0.10 | Â | Â | <0.01 | Â | Â | 0.80 | ||
Reduced | 163 (50.3) | 71 (52.2) | 134 (47.7) | 100 (55.9) | 34 (34.3) | 200 (55.4) | 39 (52.7) | 195 (50.9) | ||||
Normal | 161 (49.7) | 65 (47.8) | 147 (52.3) | 79 (44.1) | 65 (65.7) | 161 (44.6) | 35 (47.3) | 188 (49.1) | ||||
Bcl- 2 | <0.01 | Â | Â | <0.01 | Â | Â | <0.01 | Â | Â | <0.01 | ||
Positive | 268 (82.0) | 35 (25.7) | 238 (83.2) | 65 (36.7) | 34 (34.7) | 269 (73.7) | 20 (27.4) | 279 (72.5) | ||||
Negative | 59 (18.0) | 101 (74.3) | 48 (16.8) | 112 (63.3) | 64 (65.3) | 96 (26.3) | 53 (73.4) | 106 (27.5) | ||||
c -Kit | Â | Â | <0.01 | Â | Â | <0.01 | Â | Â | 1.00 | Â | Â | <0.01 |
Positive | 15 (4.5) | 18 (13.2) | 11 (3.8) | 22 (12.3) | 7 (7.1) | 26 (7.1) | 16 (21.6) | 16 (4.1) | ||||
Negative | 315 (95.5) | 118 (86.8) | 276 (96.2) | 157 (87.7) | 92 (92.9) | 341 (92.9) | 58 (78.4) | 371 (95.9) | ||||
c- Met | 0.42 | Â | Â | 0.16 | Â | Â | <0.01 | Â | Â | 0.046 | ||
Positive | 229 (71.3) | 99 (75.6) | 194 (70.0) | 134 (76.6) | 81 (84.4) | 247 (69.4) | 60 (82.2) | 267 (70.8) | ||||
Negative | 92 (28.7) | 32 (24.4) | 83 (30.0) | 41 (23.4) | 15 (15.6) | 109 (30.6) | 13 (17.8) | 110 (29.2) | ||||
Survivin | Â | Â | 0.03 | Â | Â | 0.06 | Â | Â | <0.01 | Â | Â | 0.24 |
Positive | 263 (80.0) | 120 (88.2) | 228 (79.7) | 155 (86.6) | 90 (91.8) | 293 (79.8) | 64 (87.7) | 314 (81.1) | ||||
Negative | 66 (20.0) | 16 (11.8) | 58 (20.3) | 24 (13.4) | 8 (8.2) | 74 (20.2) | 9 (12.3) | 73 (18.9) | ||||